Alpha-9 Oncology

Alpha-9 Oncology is a private, clinical-stage biotech pioneering next-generation radiopharmaceuticals for cancer. Spun out from the University of British Columbia and BC Cancer, the company leverages a proprietary, iterative design platform to create targeted therapies using isotopes like Actinium-225 and Lutetium-177. With a pipeline advancing into Phase 1 trials, strategic isotope supply agreements, and backing from top-tier investors following a Series C in 2024, Alpha-9 is positioned to accelerate the development of precision oncology treatments. The company operates dual R&D facilities in Vancouver and a corporate office in Boston.

Bespoke, iterative design platform for optimizing radiopharmaceutical molecules. It engineers all components (binder, linker, chelator, radioisotope) for selectivity and potency, and employs a theranostic development strategy using imaging agents to de-risk therapeutic trials.

The radiopharmaceutical field is highly competitive, featuring large pharma (e.g., Novartis with Pluvicto) and numerous biotech companies. Alpha-9's differentiation lies in its bespoke, iterative engineering platform and integrated theranostic development strategy. Success will depend on demonstrating superior targeting, efficacy, or safety profiles for its novel candidates.